It is estimated that in 2007, 33.2 million people worldwide were living with HIV, and in that year 2.1 million people died of Acquired Immune Deficiency Syndrome (AIDS). As the HIV epidemic continues the radiologist will increasingly assess breast masses in this population group.
Gynaecomastia is enlargement of the male breast secondary to stromal proliferation and ductal hyperplasia [9] .Possible mechanisms for gynaecomastia in HIV infected males are hypogonadism (as evidenced by a significantly lower free testosterone level) and drug therapy (e.g. anti-tuberculous drugs) [2, 4] .
With the introduction of highly active antiretroviral therapy (HAART), breast enlargement emerged as a side effect. The incidence of gynaecomastia in patients treated with highly active antiretroviral therapy for more than 2 years is estimated at 2.8% [15] .The mean delay of appearance of gynaecomastia following initiation of HAART is 9 months [4] .Gynaecomastia is initially unilateral but progresses to bilateral, but asymmetric, disease in more than half the patients [4, 6] .
HAART consists of three or more combination antiretrovirals initiated when the CD4+ counts decline. Antiretrovirals are classified according to the phase of the retrovirus life cycle they inhibit. Commonly nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors are used in combination. The principle of HAART is to decrease the incidence of drug resistant strains emerging on therapy [3] .
HAART associated gynaecomastia may be related to oestrogen or progesterone mimics at peripheral sites [4] . Another hypothesis is the immune restoration process which is the recovery of the immune system due to viral suppression by HAART. HAART improves helper T cytokine response which improves oestrogen availability producing gynaecomastia [5] .
In this setting most breast masses are due to true gynaecomastia or lipomastia. Lipomastia/ pseudogynaecomastia may appear as part of the HAART associated lipodystrophy syndrome (peripheral lipoatrophy and central lipohypertrophy). Lipomastia would appear radiolucent on mammogram [7] .
The most important differential diagnosis is that of a breast malignancy. Clinically a firm, eccentric mass is palpable. There may be associated skin changes and a possible history of nipple discharge. Pathological axillary adenopathy is present in 50% of cases at the time of diagnosis [7, 9] . Mammographic findings include a well circumscribed or spiculated mass which may have associated microcalcifications and skin thickening [9] .
Opportunistic infection, lymphoma, Kaposi's sarcoma and pseudoangiomatous stromal hyperplasia (PASH) form part of the further differential diagnosis [3, 7] . Infection should be considered in a patient with an acute history with appropriate clinical features i.e. a tender, erythematous, swollen breast. An infective process may be complicated by abscess formation which sonographically appears as an inhomogeneous mass with possible areas of breakdown.
Breast lymphoma may be primary or secondary. The masses may be solitary or multiple and may involve one or both breasts. Mammographically the breast masses lack the classical features of malignancy e.g. spiculation and microcalcification [9] .
Kaposi's sarcoma may be primary or secondary as part of disseminated disease. It may present as a breast mass or as a purple to red cutaneous lesion. Imaging features vary from mimicking malignancy to hypoechoic masses on ultrasound to features of gynaecomastia on imaging [16] .
PASH is a benign myofibroblastic process and may present as a rapidly growing breast mass. It is a well circumscribed round to oval mass on mammogram. On ultrasound it is well circumscribed with a macrolobulated contour with mixed but predominantly hypoechoic internal echoes [9, 16] .
Routinely imaging clinical gynaecomastia in a non HIV setting is controversial as some authors believe that imaging should be performed only if malignancy is suspected. The role of imaging the breasts in the setting of HIV/AIDS has not been defined but a lower threshold for imaging may be indicated in this group [13] .
Three patterns of gynaecomastia are recognised mammographically .The early nodular pattern demonstrates a defined subareolar mass which extends posteriorly in a fan like configuration. The late dendritic phase has a central mass associated with linear projections into the deep breast tissues. The diffuse glandular pattern mimics the appearance of the female breast but lacks Cooper ligaments [9] .
Sonographically the early nodular phase demonstrates a small hypoechoic subareolar mass with prominent ducts. The late dendritic phase shows posterior finger like projections in addition to the subareolar mass. The diffuse glandular pattern appears similar to the female breast [9] .
Management of gynaecomastia associated with HAART includes several options. There are few studies with small numbers addressing this issue and therefore there are no definitive treatments as yet [6] . Spontaneous resolution may occur [3] . Sometimes discontinuation of an antiretroviral drug may reverse gynaecomastia [6] .
Testosterone is safe and effective both transdermally or intramuscularly [4] . Percutaneous dihydrotestosterone gel (5g daily given once daily for 1-3 months) may be used [5] .
Limited studies that have demonstrated success with Tamoxifen 10-20mg twice daily for recent onset and tender gynaecomastia [8, 14] .
DISCUSSION
Fibrous tissue develops after one year with minimal chance of regression or response to medical therapy. Surgery may then be considered [6] .
The radiologist needs to be aware of HAART associated gynaecomastia and to be able to differentiate this from other breast pathology in the setting of an immuno compromised patient. Within the current context of the HIV/ AIDS epidemic the radiologist needs to understand the relationship between HIV, antiretroviral treatment and gynaecomastia. 
Pseudogynaecomastia/ lipomastia
Fatty infiltration which is radiolucent on mammography.
No ductal or stromal development. Fatty infiltration.
Opportunistic infection
Especially in setting of immune compromise. Clinical features and history will confirm an acute process with appropriate signs of infection.
If an abscess develops ultrasound may show a heterogeneous mass with breakdown and surrounding oedema.
Pseudoangiomatous stromal hyperplasia.
Benign myofibroblastic process. Well circumscribed, round or oval mass. Calcification not common.
Usually circumscribed mass with macrolobulated margins. Mixed but predominantly hypoechoic internal echoes.
Lymphoma
Solitary or multiple masses. May be bilateral. Masses lack spiculation, calcification or architectural distortion.
Usually mixed echogenicity, but may be homogenous and hyper or hypoechoic.
Kaposi's sarcoma
May be primary or secondary. Imaging features vary. May mimic malignancy on mammogram.
Features vary from a hypoechoic area on ultrasound to mimicking malignancy. 
